Epidemiology, Diagnosis, andManagement ofClostridium difficile Infection in Patients with Inflammatory Bowel Disease
暂无分享,去创建一个
[1] Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) , 2019, Case Medical Research.
[2] J. Fang,et al. Systematic review with meta‐analysis: long‐term outcomes of faecal microbiota transplantation for Clostridium difficile infection , 2016, Alimentary pharmacology & therapeutics.
[3] P. Malani,et al. Expanded Evidence for Frozen Fecal Microbiota Transplantation for Clostridium difficile Infection: A Fresh Take. , 2016, JAMA.
[4] P. Moayyedi,et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. , 2016, JAMA.
[5] D. Gerding,et al. Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II) , 2015 .
[6] C. Surawicz,et al. Fecal microbiota transplantation: current clinical efficacy and future prospects , 2015, Clinical and experimental gastroenterology.
[7] H. Szajewska,et al. Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea , 2015, Alimentary pharmacology & therapeutics.
[8] C. Sears,et al. Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease , 2015, Alimentary pharmacology & therapeutics.
[9] T. Monaghan,et al. Pathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.
[10] E. Zoetendal,et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.
[11] M. Surette,et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.
[12] D. Raoult,et al. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report , 2015, European Journal of Clinical Microbiology & Infectious Diseases.
[13] Antonio Ramos,et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. , 2015, JAMA.
[14] A. Gasbarrini,et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection , 2015, Alimentary pharmacology & therapeutics.
[15] L. Mcfarland. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review , 2015, Antibiotics.
[16] A. Galecki,et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] P. Malani,et al. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. , 2015, JAMA.
[18] G. Russell,et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. , 2014, JAMA.
[19] A. Wollam,et al. Phenotypic and Genotypic Analysis of Clostridium difficile Isolates: a Single-Center Study , 2014, Journal of Clinical Microbiology.
[20] J. Bakken. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] A. Ananthakrishnan,et al. Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. , 2014, The New England journal of medicine.
[22] D. Nathwani,et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection , 2014, The Journal of antimicrobial chemotherapy.
[23] N. Hotte,et al. Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. , 2014, Journal of clinical gastroenterology.
[24] M. Wallace,et al. Tempered enthusiasm for fecal transplant. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] L. Valiquette,et al. Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review , 2014, PloS one.
[26] M. Mellow,et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients , 2014, The American Journal of Gastroenterology.
[27] Jenny Sauk,et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] T. Louie,et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] A. Kostic,et al. The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.
[30] Jie Liang,et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children , 2014, Alimentary pharmacology & therapeutics.
[31] T. Riley,et al. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.
[32] D. Aronoff,et al. The Systemic Inflammatory Response to Clostridium difficile Infection , 2014, PloS one.
[33] M. P. Bauer,et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[34] Bo Li,et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection , 2014, Nature Communications.
[35] E. Lofgren,et al. A Mathematical Model to Evaluate the Routine Use of Fecal Microbiota Transplantation to Prevent Incident and Recurrent Clostridium difficile Infection , 2014, Infection Control & Hospital Epidemiology.
[36] K. Carroll,et al. Clostridium difficile Carriage and Serum Antitoxin Responses in Children with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.
[37] C. Buffie,et al. Microbiota-mediated colonization resistance against intestinal pathogens , 2013, Nature Reviews Immunology.
[38] M. Trauner,et al. Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients After Fecal Microbiota Transplantation , 2013, The American Journal of Gastroenterology.
[39] A. Galecki,et al. Poor Functional Status as a Risk Factor for Severe Clostridium difficile Infection in Hospitalized Older Adults , 2013, Journal of the American Geriatrics Society.
[40] M. Icaza-Chávez,et al. Microbiota intestinal en la salud y la enfermedad , 2013 .
[41] W. Petritsch,et al. Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis , 2013, Inflammatory bowel diseases.
[42] C. Umscheid,et al. Is fidaxomicin worth the cost? An economic analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] B. Currie,et al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital , 2013, Current medical research and opinion.
[44] D. Aronoff,et al. A clinical and epidemiological review of non-toxigenic Clostridium difficile. , 2013, Anaerobe.
[45] V. Mai,et al. Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.
[46] E. Nagy,et al. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] Ashwin N Ananthakrishnan,et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections , 2013, The American Journal of Gastroenterology.
[48] D. Hutton,et al. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[49] A. Testro,et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. , 2013, European journal of gastroenterology & hepatology.
[50] E. Zoetendal,et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.
[51] J. Jansson,et al. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota , 2013, The ISME Journal.
[52] G. Guyatt,et al. Probiotics for the Prevention of Clostridium difficile–Associated Diarrhea , 2012, Annals of Internal Medicine.
[53] Philip Smith,et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient , 2012, Transplant infectious disease : an official journal of the Transplantation Society.
[54] M. Falagas,et al. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[55] Mark A. Miller,et al. Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] Neil Stollman,et al. Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.
[57] Susanne Hempel,et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. , 2012, JAMA.
[58] T. Wilt,et al. Comparative Effectiveness of Clostridium difficile Treatments , 2011, Annals of Internal Medicine.
[59] K. Garey,et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. , 2011, The Journal of antimicrobial chemotherapy.
[60] A. Manges,et al. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[61] J. Sarma,et al. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. , 2011, The Journal of hospital infection.
[62] A. Viale,et al. Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis , 2011, Infection and Immunity.
[63] Linda M. Spooner,et al. Tigecycline for the Treatment of Severe Clostridium difficile Infection , 2011, The Annals of pharmacotherapy.
[64] April D. Miller,et al. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[65] P. Moayyedi,et al. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: Antibiotics alone or combined antibiotics/immunomodulators? , 2011, Inflammatory bowel diseases.
[66] M. Wilcox,et al. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. , 2011, The Journal of antimicrobial chemotherapy.
[67] Patrick D Schloss,et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection , 2011, Gut microbes.
[68] G. French,et al. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. , 2011, The Journal of infection.
[69] Joshua A. Doherty,et al. Development and Validation of a Clostridium difficile Infection Risk Prediction Model Author ( s ) : , 2018 .
[70] D. Rampton,et al. Systematic review: Clostridium difficile and inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.
[71] J. Kelsen,et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease , 2011, Inflammatory bowel diseases.
[72] A. Ananthakrishnan,et al. Impact of Clostridium difficile on inflammatory bowel disease , 2010, Expert review of gastroenterology & hepatology.
[73] L. Brandt,et al. Glucocorticoids Are Associated With Increased Risk of Short-Term Mortality in Hospitalized Patients With Clostridium difficile-Associated Disease , 2010, The American Journal of Gastroenterology.
[74] J. Maul,et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. , 2010, Journal of Crohn's & colitis.
[75] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[76] Roger Baxter,et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. , 2010, The New England journal of medicine.
[77] D. Gerding,et al. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. , 2009, Anaerobe.
[78] H. Epple. Therapy- and Non-Therapy-Dependent Infectious Complications in Inflammatory Bowel Disease , 2009, Digestive Diseases.
[79] J. O’Horo,et al. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[80] J. Maul,et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[81] R. P. Ross,et al. The Vexed Relationship Between Clostridium Difficile and Inflammatory Bowel Disease: An Assessment of Carriage in an Outpatient Setting Among Patients in Remission , 2009, The American Journal of Gastroenterology.
[82] Hilary G. Morrison,et al. Reproducible Community Dynamics of the Gastrointestinal Microbiota following Antibiotic Perturbation , 2009, Infection and Immunity.
[83] D. Musher,et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[84] D. Musher,et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] P. Rutgeerts,et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[86] Les Dethlefsen,et al. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing , 2008, PLoS biology.
[87] J. Doré,et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.
[88] M. A. Franzos,et al. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. , 2008, Annals of internal medicine.
[89] D. Antonopoulos,et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. , 2008, The Journal of infectious diseases.
[90] Ken Kleinman,et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[91] P. Rampal,et al. Low risk of irritable bowel syndrome after Clostridium difficile infection. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[92] Wendy S. Garrett,et al. Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.
[93] N. Pace,et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.
[94] M. Segarra-Newnham,et al. Probiotics for Clostridium difficile–Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii , 2007, The Annals of pharmacotherapy.
[95] D. Musher,et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. , 2007, The Journal of antimicrobial chemotherapy.
[96] E. Mardis,et al. An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.
[97] F. Friedenberg,et al. Continuation of Antibiotics Is Associated With Failure of Metronidazole for Clostridium difficile-Associated Diarrhea , 2006, Journal of clinical gastroenterology.
[98] Stuart Johnson,et al. An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.
[99] C. Manichanh,et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.
[100] Jon Brazier,et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.
[101] D. Musher,et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[102] T. Borody,et al. Treatment of Ulcerative Colitis Using Fecal Bacteriotherapy , 2003, Journal of clinical gastroenterology.
[103] M. Stevenson,et al. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. , 2003, The Journal of antimicrobial chemotherapy.
[104] C. Kelly,et al. Underlying Disease Severity as a Major Risk Factor for Nosocomial Clostridium difficile Diarrhea , 2002, Infection Control & Hospital Epidemiology.
[105] A. Apisarnthanarak,et al. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[106] Lynne V McFarland,et al. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.
[107] G. Macfarlane,et al. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. , 2002, Journal of medical microbiology.
[108] C E Nord,et al. Effect of antimicrobial agents on the ecological balance of human microflora. , 2001, The Lancet. Infectious diseases.
[109] C. Pothoulakis,et al. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[110] C. Kelly,et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.
[111] C. Kelly,et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.
[112] M. Samore,et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea , 1998, The Lancet.
[113] D. Gerding,et al. Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991 , 1994, Infection Control & Hospital Epidemiology.
[114] L. Peterson,et al. Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole , 1992, Annals of Internal Medicine.
[115] L. Peterson,et al. Nosocomial Clostridium difficile colonisation and disease , 1990, The Lancet.
[116] T. Borody,et al. Bowel‐flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? , 1989, The Medical journal of Australia.
[117] J. Bennet,et al. TREATMENT OF ULCERATIVE COLITIS BY IMPLANTATION OF NORMAL COLONIC FLORA , 1989, The Lancet.
[118] S. Borriello,et al. An in-vitro model of colonisation resistance to Clostridium difficile infection. , 1986, Journal of medical microbiology.
[119] A. Pantosti,et al. Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine , 1985, Antimicrobial Agents and Chemotherapy.
[120] J. Bartlett,et al. Treatment of antibiotic-associated pseudomembranous colitis. , 1984, Reviews of infectious diseases.
[121] J. Bartlett,et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.
[122] G. Alangaden,et al. Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[123] J. Meek,et al. Burden of Clostridium difficile infection in the United States. , 2015, The New England journal of medicine.
[124] C. Kelly,et al. Clostridium difficile infection in the inflammatory bowel disease patient. , 2013, Inflammatory bowel diseases.
[125] Duolao Wang,et al. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). , 2013, Health technology assessment.
[126] M. Wilcox. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[127] R. Orenstein,et al. Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis. , 2012, Revista de Gastroenterología de México.
[128] D. Gerding. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. , 2012, Discovery medicine.
[129] Guang-xi Li,et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .
[130] K. Mølbak,et al. Binary toxin and death after Clostridium difficile infection. , 2011, Emerging infectious diseases.
[131] E. Kuijper,et al. Emergence of Clostridium difficile-associated disease in North America and Europe. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[132] T. Barton,et al. Rectal use of vancomycin. , 1994, The Annals of pharmacotherapy.
[133] J. Silva,et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. , 1989, The American journal of medicine.